Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone
- PMID: 16247790
- DOI: 10.1002/cncr.21478
Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone
Erratum in
-
Erratum: Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone.Cancer. 2015 Sep 1;121(17):3048. doi: 10.1002/cncr.29458. Epub 2015 May 8. Cancer. 2015. PMID: 26291439 No abstract available.
Abstract
Background: There are three distinct types of doxorubicin-induced cardiotoxicity (acute, chronic, and late-onset). Although previous studies with animal models suggest that angiotensin II plays a key role in the process of the doxorubicin-induced cardiotoxicity, there has been no such observation in humans. This randomized study investigated whether valsartan, a new class of angiotensin II receptor blocker (ARB), can inhibit acute cardiotoxicity after doxorubicin-based chemotherapy.
Methods: Forty consecutive patients with untreated non-Hodgkin lymphoma who were scheduled to undergo standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) (mean age, 56 yrs; range, 24-70 yrs) were randomized with minimization methods to receive CHOP with or without 80 mg/day of valsartan. Acute cardiotoxicity was comprehensively evaluated with neurohumoral, echocardiographic, and electrocardiographic markers before and on Days 3, 5, and 7 after the initiation of CHOP.
Results: CHOP induced transient increases in the left ventricular end-diastolic diameter in an echocardiogram, the QTc interval and QTc dispersion in an electrocardiogram, and in the plasma brain and atrial natriuretic peptides. All these changes returned to nearly normal levels within a week after CHOP (P < 0.001). Notably, valsartan significantly prevented all these changes except for the elevation in atrial natriuretic peptide (P < 0.05). No significant change was observed in blood pressure or heart rate between the valsartan and control groups.
Conclusions: The results indicate that angiotensin II may play an essential role in acute CHOP-induced cardiotoxicity in humans. Future long-term studies are necessary to judge whether ARBs have a potential to prevent the chronic or late-onset types of doxorubicin-induced cardiotoxicity.
Similar articles
-
Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349).J Clin Oncol. 2003 Jul 1;21(13):2466-73. doi: 10.1200/JCO.2003.06.137. J Clin Oncol. 2003. PMID: 12829664 Clinical Trial.
-
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.Lancet. 2013 May 25;381(9880):1817-26. doi: 10.1016/S0140-6736(13)60313-X. Epub 2013 Apr 22. Lancet. 2013. PMID: 23615461 Clinical Trial.
-
Neuroendocrine changes during the evolution of doxorubicin-induced left ventricular dysfunction in adult lymphoma patients.Clin Sci (Lond). 2001 Dec;101(6):601-7. Clin Sci (Lond). 2001. PMID: 11724646 Clinical Trial.
-
Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.Hypertens Res. 2007 Apr;30(4):307-13. doi: 10.1291/hypres.30.307. Hypertens Res. 2007. PMID: 17541209 Clinical Trial.
-
New treatment strategies for aggressive lymphoma.Semin Oncol. 2004 Dec;31(6 Suppl 15):10-3. doi: 10.1053/j.seminoncol.2004.11.022. Semin Oncol. 2004. PMID: 15726533 Review.
Cited by
-
Adjuvant breast cancer treatments cardiotoxicity and modern methods of detection and prevention of cardiac complications.ESC Heart Fail. 2021 Aug;8(4):2397-2418. doi: 10.1002/ehf2.13365. Epub 2021 May 5. ESC Heart Fail. 2021. PMID: 33955207 Free PMC article. Review.
-
Cardiotoxicity of cancer therapeutics: current issues in screening, prevention, and therapy.Front Pharmacol. 2013 Mar 12;4:19. doi: 10.3389/fphar.2013.00019. eCollection 2013. Front Pharmacol. 2013. PMID: 23487556 Free PMC article.
-
Protecting the heart in cancer therapy.F1000Res. 2018 Sep 28;7:F1000 Faculty Rev-1566. doi: 10.12688/f1000research.15190.1. eCollection 2018. F1000Res. 2018. PMID: 30345014 Free PMC article. Review.
-
Anthracycline-associated cardiotoxicity in survivors of childhood cancer.Pediatr Cardiol. 2011 Mar;32(3):342-53. doi: 10.1007/s00246-010-9878-3. Epub 2011 Jan 9. Pediatr Cardiol. 2011. PMID: 21221562
-
Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions.Circ Heart Fail. 2016 Feb;9(2):e002843. doi: 10.1161/CIRCHEARTFAILURE.115.002843. Circ Heart Fail. 2016. PMID: 26839395 Free PMC article. Review.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Research Materials